Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region A Cross-sectional Multi-center, Observational Study to Describe the Disease Characteristics and Treatment Patterns and Explore Access to Novel Therapies for Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Both Treatment naïve and Relapsed/Refractory Patients in the Middle East & Africa (MEA) Region.

NCT07065344 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07065344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07065344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region A Cross-sectional Multi-center, Observational Study to Describe the Disease Characteristics and Treatment Patterns and Explore Access to Novel Therapies for Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Both Treatment naïve and Relapsed/Refractory Patients in the Middle East & Africa (MEA) Region.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
July 23, 2025
Completion date
January 31, 2027
Enrollment
500 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

diffused large b cell lymphoma, hematology